Cas:497057-04-2 4-methyl-9H-pyrido[3,4-b]indole manufacturer & supplier

We serve Chemical Name:4-methyl-9H-pyrido[3,4-b]indole CAS:497057-04-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-methyl-9H-pyrido[3,4-b]indole

Chemical Name:4-methyl-9H-pyrido[3,4-b]indole
CAS.NO:497057-04-2
Synonyms:4-methyl-9H-pyrido[3,4-b]indole
Molecular Formula:C12H10N2
Molecular Weight:182.22100
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:28.68000
Exact Mass:182.08400
LogP:3.02450

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-methyl-9H-pyrido[3,4-b]indole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-methyl-9H-pyrido[3,4-b]indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-methyl-9H-pyrido[3,4-b]indole Use and application,4-methyl-9H-pyrido[3,4-b]indole technical grade,usp/ep/jp grade.


Related News: The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 4-methyl-9H-pyrido[3,4-b]indole manufacturer The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years. 4-methyl-9H-pyrido[3,4-b]indole supplier British Airways, Qantas and Lufthansa — among others — have announced they will stop flying to mainland China. Other airlines are reducing the number of flights. 4-methyl-9H-pyrido[3,4-b]indole vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL. 4-methyl-9H-pyrido[3,4-b]indole factory The oral form of rigosertib was developed to provide a potentially more convenient dosage form for use where the duration of treatment may extend to multiple years.